None
Quote | Outlook Therapeutics Inc. (NASDAQ:OTLK)
Last: | $7.07 |
---|---|
Change Percent: | -0.55% |
Open: | $7.26 |
Close: | $7.07 |
High: | $7.35 |
Low: | $6.89 |
Volume: | 166,599 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Outlook Therapeutics Inc. (NASDAQ:OTLK)
2024-05-28 11:50:44 ET More on Outlook Therapeutics Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval Outlook Therapeutics shares rise after 'buy' rating f...
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...
Message Board Posts | Outlook Therapeutics Inc. (NASDAQ:OTLK)
Subject | By | Source | When |
---|---|---|---|
znewcar1: OTLK 21% v25,6M c1.79 f162M H1.85 morning pop got S@1.55 then sideways strong aft | znewcar1 | investorshangout | 02/04/2021 11:15:59 PM |
znewcar1: OTLK 27% v28,8M c1.47 f127M H1.65 got S@1.35 | znewcar1 | investorshangout | 02/03/2021 10:35:16 PM |
znewcar1: OTLK 20% v6,6M c1.050 f91,3M H1.09 S.92 | znewcar1 | investorshangout | 05/27/2020 8:59:40 PM |
znewcar1: OTLK 48% v6,0M c.875 f38M late day BO over .65 S@.7 then HOD.95 S.81 | znewcar1 | investorshangout | 01/03/2020 12:46:38 AM |
znewcar1: OTLK 53% v6,1M c1.59 f28,M H 1.74 After hour gap and fad then @10 BO1.19 H1.74 S1.50 and e | znewcar1 | investorshangout | 12/03/2019 9:15:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...
2024-05-16 12:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma) United Kingdom (UK) Marketing Authorization Application (MAA) submitted NORSE EIGHT fully underway in the U...